Evogene (NASDAQ:EVGN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.72) by 108.33 percent. This is a 104.62 percent increase over losses of $(1.30) per share from the same period last year. The company reported quarterly sales of $1.61 million which missed the analyst consensus estimate of $3.63 million by 55.56 percent. This is a 178.72 percent increase over sales of $578.00 thousand the same period last year.